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Non-small Cell Lung Cancer Induces an
Immunosuppressive Phenotype of Dendritic Cells in Tumor
Microenvironment by Upregulating B7-H3
Thomas Schneider, MD,* Hans Hoffmann, MD, PhD,* Hendrik Dienemann, MD, PhD,*
Philipp A. Schnabel, MD, PhD,† Alexander H. Enk, MD,‡ Sabine Ring, PhD,‡
and Karsten Mahnke, PhD‡
Introduction: Tumors may shift the phenotype and function of
dendritic cells (DC) toward the induction of tolerance. In the status
of full maturity, DC express a multitude of T cell costimulatory
molecules enabling them to induce immune reactions, whereas
nonactivated resident DC lack these T cell stimulating capacities.
Therefore, we investigated the changes in DC phenotype and ex-
pression of B7-H molecules induced by non-small cell lung cancer
(NSCLC).
Methods: The expression of T cell coinhibitory B7 molecules
(B7-DC, B7-1, B7-2, B7-H1, B7-H3) on DC isolated from malig-
nant and nonmalignant lung and lymph node tissue from patients
attending curative surgery for NSCLC (n 12) was analyzed. T cell
stimulatory functions of DC isolated from malignant and nonmalig-
nant lung and lymph node tissue samples were measured by allo-
geneic mixed lymphocyte reactions. Furthermore, the secretion of
IL-10 and IL-12p40 by DC was analyzed (enzyme-linked immu-
nosorbent assay).
Results: B7-H3 was significantly upregulated in tumor-residing DC,
whereas the expression of other B7 molecules, such as B7-DC,
B7-1, B7-2, B7-H1, remained unchanged. Significantly reduced
levels of T cell proliferation in mixed lymphocyte reactions with
tumor-derived DC were recorded. Moreover, elevated concentra-
tions of IL-10 were measured in tumor-derived DC, whereas IL-12
levels were reduced.
Conclusion: Our data indicate that (1) DC derived from NSCLC are
immunosuppressive, and (2) under tumor conditions the coinhibitory
molecule B7-H3 plays a crucial role in mediating the T cell sup-
pressive effects of DC.
Key Words: B7-H3, Dendritic cells, Lung cancer, Tumor microen-
vironment, Immunosuppression.
(J Thorac Oncol. 2011;6: 1162–1168)
Lung cancer is the leading cause of cancer death withgrowing incidence in both developed and developing
countries. The prognosis remains poor, and the need for novel
therapy approaches is apparent.1,2 Particularly, in immuno-
genic malignancies, such as malignant melanoma and renal
carcinoma, dendritic cell (DC)-based vaccinations have
shown promising results but also in lung cancer clinical trials
were successfully completed.3–6 Indeed, DC are a highly
heterogeneous cell population, and numerous functional sub-
sets have been identified.7 In the status of full maturity, DC
express a multitude of T cell costimulatory molecules en-
abling them to induce immune reactions, whereas nonacti-
vated resident DC lack these T cell stimulating capacities.8
Despite the constant immune monitoring of the body by DC,
apparently several tumors create a privileged microenviron-
ment that protects cancer cells from immune destruction. The
underlying means by which non-small cell lung cancer
(NSCLC) escapes immune surveillance by DC are not com-
pletely understood; however, similar to other types of cancer
such as melanoma, NSCLC has clearly immunosuppressive
activity, as it raises the frequency as well as the suppressive
capacity of regulatory T cells.9,10 Moreover, NSCLC stimu-
lates the release of immunosuppressive cytokines by PBMC
and induces expression of suppressive surface molecules,
such as the programmed cell death-1 receptor on CD8 T
cells.11,12 In addition to inducing immunosuppressive mole-
cules that can act directly on effector cells of the immune
system, NSCLC is also able to prevent the induction of
immunity by influencing DC. Here, NSCLC inhibits the
maturation of DC and keeps them in an immature and hence
less immunogenic state.13,14 Interestingly, the observed aug-
mented frequency of Treg in NSCLC patients may be attrib-
utable to the effects of NSCLC exerted on DC, as NSCLC-
derived DC produce high amounts of TGF- and are strong
inducers of Treg.15 Thus, NSCLC is able to circumvent
induction of immunity at least in part by affecting DC
maturation and activation. Not only the abrogation of DC
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maturation but also the induction of cell surface expression of
T cell suppressive molecules on DC has been described in
various tumors. Among those molecules that may inhibit
immune reactions, members of the B7-H family are known to
be upregulated in tumor conditions.16 These molecules
convey mainly suppressive signals inhibiting cytokine pro-
duction and T cell proliferation in vitro and in vivo. In
light of these data, we investigated the changes in DC
phenotype and the expression of B7-H molecules induced
by NSCLC. Therefore, we analyzed DC isolated from ma-
lignant and nonmalignant lung and lymph node tissue sam-
ples for surface molecule expression and T cell stimulatory
functions and found that the inhibitory molecule B7-H3 and
the secretion of the immunosuppressive cytokine IL-10 is
upregulated in NSCLC-derived DC.
METHODS
Patients
A total of 12 patients who underwent curative resection
of NSCLC (adenocarcinoma) were enrolled in this study;
none were subjected to preoperative chemotherapy and/or
radiotherapy. Lobectomy with radical mediastinal and hilar
lymphadenectomy was performed in all patients. The post-
operative pathologic stage for lung cancer was determined
according to the seventh Tumor Node Metastasis classifica-
tion system, revised in 2009.17 The Ethics Committee of the
University of Heidelberg approved this study (Study No.
270/2001). Each patient was informed comprehensively;
written consent was given before participation.
Processing of Tissue Specimens
Immediately after surgical resection, tissue samples
were extracted. Tumor tissue was taken from an area of solid
tumor tissue lacking the gross aspect of massive necrosis. For
the representative tumor-free lung tissue samples, tissue was
taken from the surgically removed lung in farthermost posi-
tion opposed to the tumor. In each patient, lymph node tissue
was taken from a typically tumor draining position. Immedi-
ate frozen sectioning proved tumor infiltration in a total of six
lymph node specimens.
Medium and Cell Reagents
All media and cell culture supply, if not stated other-
wise, were obtained from PAA, Co¨lbe, Germany. Falcon
tissue culture plasticware was obtained from Becton Dickin-
son, Heidelberg, Germany.
Single Cell Suspensions
Single cell suspensions of lymph nodes, lung tissue,
and lung tumor samples were obtained using Collagenase/
Trypsin digestion. Briefly, tissues were cut in pieces by
scalpels and placed in petri dishes containing 4000 U/ml
Collagenase IV (Cell systems, Troisdorf, Germany), 0.1%
(wt/vol) Trypsin (Sigma, Deisenhofen, Germany), 1 mg/ml
DNAse I (Sigma) and incubated at 37°C for 25 minutes.
Thereafter, ethylenediaminetetraacetic acid (Sigma) was
added to a final concentration of 1 mM. After additional 5
minutes incubation, the samples were placed into a cell
grinder (Becton Dickinson, Heidelberg, Germany) and pro-
cessed for 5 minutes. Thereafter, the suspension was filtered
through a 0.2-m cell strainer (Becton Dickinson, Heidel-
berg, Germany), centrifuged (1.200 rpm, 4°C, 7 minutes), and
washed three times with RPMI medium.
FACS Analysis
For flow cytometry (FACS) analysis, cells were ad-
justed to 1  106/200 l in phosphate-buffered saline (PBS)
1% fetal calf serum (FCS) (vol/vol) and kept on ice. For
staining, cells were incubated with FITC-labeled anti-B7DC,
anti-B7H1, anti-B7H3, anti B7–1, or anti B7–2 antibodies,
respectively, at a final dilution of 1 g/ml. PE-labeled anti-
CD11c antibodies (1 g/ml, final dilution) were added simul-
taneously, and cells were incubated for 45 minutes at 4°C (all
antibodies were obtained from e-Bioscience, Frankfurt, Ger-
many). Thereafter, samples were washed three times (PBS
1% vol/vol FCS) and analyzed using a FACS Canto (Becton
Dickinson). To check the purity of the suspension and the
quality of the obtained cells, additional FACS analyses were
performed using antibodies defining granulocytes (CD16) and
macrophages (CD14; both from Becton Dickinson, Heidelberg).
Isolation of DC and T Cells
The isolation of DC was performed using CD11c-
specific MACS MicroBeads (Miltenyi, Bergisch Gladbach,
Germany) according to the manufacturer’s protocol. Briefly,
single cell suspensions were diluted in MACS buffer (PBS
0.5% vol/vol BSA, 2 mM ethylenediaminetetraacetic acid)
and CD11c micro beads were added. To increase specificity,
half the number of beads as indicated in the manufacturer’s
protocol was added, resulting in a higher purity of the isolated
DC. Samples were kept for 45 minutes at 4°C in a rotary
shaker. Thereafter, cells were washed three times with ice-
cold MACS buffer and placed into MACS buffer equilibrated
paramagnetic columns. The columns were washed with 10 ml
MACS buffer and the flow through was discarded. Subse-
quently, columns were removed from the magnetic field and
the CD11c cells were flushed out, washed, and collected by
centrifugation. CD4 responder T cells were obtained from
20 ml blood of healthy volunteers using the “untouched T cell
kit” (Miltenyi) according the manufacturer’s protocol.
Briefly, PBMC were incubated with a cocktail of biotinylated
antibodies directed against CD8 T cells and non-T cells.
After incubation, streptavidin-coated beads were added and
the cells were subjected to a paramagnetic column. The flow
through was collected and washed. Routinely FACS analysis
of the purified CD11c cells and of the CD4 T cells were
performed, indicating yields of 80% CD11c cells for the
DC fraction and 95% for the CD4 T cell fraction.
Proliferations Assays and Cytokines
For proliferation assays, 5  104 DC were cocultivated
with 1  105 CD4 T cells in 200 l complete RPMI
medium, supplemented with 10% FCS (vol/vol) in 96-well
round bottom plates. As positive control, T cells were stim-
ulated with anti-CD3 (1 g/ml) and anti-CD28 (2 g/ml)
antibodies (e-Bioscience, Frankfurt, Germany). As indicated
in the text, to some samples anti-B7-H3 antibodies and
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respective isotype controls (both from e-bioscience) were
added (final dilution: 10 g/ml). Cultures were incubated at
37°C, 5% CO2 for 4 days. For the last 18 hours of culture, 0.5
Ci/ml [3H]-Thymidine (Amersham, Frankfurt, Germany)
was added. Cells were harvested and Thymidine incorpora-
tion was determined using a PerkinElmer (Rodgau, Germany)
scintillation counter. For the determination of cytokine pro-
duction of DC, 105 DC were cultivated for 24 hours in
96-well plates in 200 l complete medium, supplemented
with 10 ng/ml lipopolysaccharides (Sigma, Germany). There-
after, 100 l of tissue culture supernatant was removed and
analyzed in triplicates for IL-10 or IL-12, respectively, using
conventional ELISA kits (e-Bioscience, Frankfurt, Germany)
and a ELISA reader (Titertek, Turku, Finland).
Statistical Analysis
As indicated in the figures, differences were tested for
significance using an unpaired, one-tailed Student’s t test.
RESULTS
DC in Tumors Upregulate B7-H3 Expression
We analyzed the expression of different member of the
B7 family (B7-DC, B7-H1, B7-H3, B7-1, B7-2) on DC
FIGURE 1. Expression of B7 molecules by dendritic cells (DC) in tumor and lung tissue. Single cell suspensions were pre-
pared from lung cancer samples (tumor) and from unaffected lung tissue (control). Suspensions were stained with antibodies
as indicated and analyzed by FACS. A, To gate for CD11c DC, autofluorescent cells were determined first by measuring the
fluorescence of the cells in the APC channel. These cells were excluded. Next, the SSChigh/CD11c cells were gated and ana-
lyzed for typical DC (HLA-DR), granulocyte (CD16), and monocyte (CD14) markers. B, Cells gated as in (A) were further ana-
lyzed for expression of B7 markers. The vertical lines depict the border between negative and positive cells as determined by
isotype controls and the number in the upper right corner displays the percentage of positive cells among the CD11c popu-
lation. A typical example for one representative patient out of four is shown.
Schneider et al. Journal of Thoracic Oncology • Volume 6, Number 7, July 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1164
isolated directly from tumor tissue in comparison to DC
extracted from healthy lung tissue from one and the same
donor. Among the molecules tested, B7-H3 was significantly
upregulated in tumor-residing DC as compared with DC
derived from healthy lungs. In contrast, expression of other
B7 molecules was not significantly altered in tumor tissue
compared with the healthy lung (Figures 1 and 2).
No substantial differences in the expression of B7
markers were apparent in tumor infiltrated lymph nodes
versus tumor-free lymph nodes, when gating on CD11c DC.
The potentially immunosuppressive molecules, B7-DC, B7-
H1, and B7-H3, were expressed by CD11c DC in tumor
infiltrated lymph nodes to a similar extend as in tumor-free
lymph nodes. Moreover, also the expression of the T cell
costimulatory molecules B7-1 (CD80) and B7-2 (CD86) did
not differ between tumor infiltrated and tumor-free lymph
nodes (Figure 3).
B7-H3 Expression by DC Impairs Their T Cell
Stimulatory Capacity
In allogeneic mixed lymphocyte reactions (MLRs), a
significantly reduced T cell proliferation was found in tumor-
derived DC as compared with the control counterparts iso-
lated from healthy lung tissue. As further controls, DC
isolated from lymph node samples of the same patient were
included; these DC were as potent in stimulating T cell
proliferation as the lung DC. Finally, addition of anti-CD3/
CD28 antibodies to the T cell cultures stimulated T cell
proliferation maximally, indicating that the isolated CD4 T
cells were viable and were able to respond to stimulation via
their T cell receptors (Figure 4).
When B7-H3 antibodies were added to the cultures of
tumor-derived DC and allogeneic T cells, increased T cell
proliferation was observed, reaching similar levels of prolif-
eration as obtained with DC purified from control lungs or
lymph nodes, respectively. This effect was specific for block-
ade of B7-H3, as addition of isotype-matched, nonbinding
antibodies did not affect the T cell proliferation. To rule out
other unspecific T cell stimulatory effects of the B7-H3
antibodies, we added the antibodies and respective isotype
controls to MLRs set up with lymph node-derived DC, which
only express basic level of the B7-H3 surface molecules and
thus should be unsusceptible to the blocking activity of
B7-H3 antibodies. In these experiments, we measured similar
T cell proliferation in antibody-treated and control samples,
indicating that anti-B7-H3 antibodies do not stimulate T cell
proliferation unspecifically (Figure 5).
Tumor-Derived DC Secrete More IL-10 and
Less IL-12p70 as Compared with Controls
To further analyze the phenotype of the tumor DC, 1 
105 magnetobead isolated DC were cultivated overnight to-
gether with 10 ng/ml LPS, and the supernatant was tested for
IL-10 and IL-12p70 content by ELISA. Significantly elevated
levels of IL-10 in cultures of tumor-derived DC were mea-
sured as compared with normal lung or lymph node DC. In
contrast, IL-12 levels were significantly reduced in cultures
of tumor DC as compared with the controls (Figure 6).
DISCUSSION
DC were originally defined as immune stimulatory
antigen presenting cells that are able to induce robust T cell
responses to various antigens. However, this function can be
corrupted by tumors. Herein, we report that tumor-derived
DC obtained from lung cancer patients express substantial
amounts of the T cell coinhibitory molecule B7-H3 and are
inferior in stimulating T cell proliferation as compared with
controls. Thus, lung tumors may create an immunosuppres-
sive environment by rendering DC immunosuppressive and
preventing the induction on antitumor T cells.
The B7-H3 molecule is a member of the programmed
death ligand (PD-L) family, which has structural similarities
to the classical T cell costimulatory molecules B7-1 and
B7-2.18 B7-1 and B7-2 have clearly T cell costimulatory
functions and are predominantly expressed by professional
APC such as DC. In contrast, B7-H3 is broadly expressed on
lymphoid organs, lung, bladder, and liver, and has dual
functions as costimulator and also as a profound T cell
coinhibitor.16,19 Its activating properties are deducted from
experiments showing that B7-H3 molecules increase prolif-
eration of CD4 and CD8 T cells and stimulate IFN
secretion.20 Murine tumor models also revealed that natural
or ectopic expression of B7-H3 on different tumor cells, such
as melanoma, colon cancer, and mastocytoma, lead to induc-
tion of tumor-specific CTL and prolonged survival time
significantly.21–23 Moreover, in pancreatic cancer, expression
of B7-H3 was associated with prolonged survival.24 How-
ever, these results were in contrast to other reports that
demonstrated immunosuppressive and therefore adverse ef-
fects of B7-H3 expression in pancreatic cancer patients.24
Nevertheless, the T cell activating effects seem to be medi-
ated by the triggering receptor expressed on myeloid cells
(TREM)-like transcript 2 (TLT-2), which is constitutively
FIGURE 2. B7-H3 is upregulated in tumor-derived dendritic
cells (DC). Upregulation of B7-H3 was found in all lung can-
cer samples compared with unaffected lung tissue. The fig-
ure shows the data of four experiments as individual dots.
The mean values are indicated as bars. *Significant differ-
ence (t test; *p  0.05).
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expressed by DC, B cells, macrophages, NK cells, and
neutrophils.25 Thus, expression of B7-H3 by tumor cells may
facilitate the cross talk between tumors and different types of
leukocytes for the purpose of immune stimulation.
However, at the same time, accumulating evidence
indicates that B7-H3 acts as a coinhibitory factor that is able
to abrogate T cell response in various cancers and during
autoimmunity.26 In a murine autoimmune model for multiple
sclerosis, the addition of recombinant B7-H3 molecules,
which mimic the action of B7-H3 expressing cells, sup-
pressed T cell proliferation in vitro.27 Moreover, immunosup-
pressive effects of B7-H3 are also apparent in vivo in human
cancer patients. Here, presence of B7-H3 in tumor vascula-
ture of renal cell carcinoma (RCC) was investigated, and the
data clearly indicate that B7-H3 expression was significantly
associated with an increased risk of death from RCC.28
Likewise, human pancreatic cancer patients displayed ele-
vated expression of B7-H3 molecules on tumor tissues, which
was even enhanced in cases with lymph node metastasis and
advanced pathological stages, indicating a strong correlation
between B7-H3 expression and a bad prognosis of survival
for cancer patients.24 The functional contribution of B7-H3 to
the impaired antitumor immunity was further strengthened by
observations in a murine pancreatic cancer model, showing
that blockade of B7-H3 molecules on cancer cells by a
monoclonal antibody resulted in a substantial antitumor effect
that was mainly due to recruitment of CD8 T cells to the
tumor site.24 Our results are in line with this inhibitory
function of B7-H3, as blockade of B7-H3 on DC did enhance
T cell proliferation in MLRs. However, these differential
effects of B7-H3 on immunity (inhibitory versus stimulatory)
may be explained by different sets of activating and/or
inhibitory counter-receptors expressed by target cells.29 In-
deed, the receptors involved in this T cell coinhibitory action
of B7-H3, as well as the signal transduction, are largely
unknown. Thus, the presence of either stimulatory or inhib-
itory counter receptors for B7-H3 on the target cells may
determine the immunological outcome of B7-H3 engage-
ment.30 Consequently, in different tumors, the action of
B7-H3 expressing DC may by different. In human NSCLC,
B7-H3 was found in cell lines as well as tumor specimens;
high expression of B7-H3 was associated with lymph node
metastasis.31 In addition, high levels of circulating B7-H3
were associated with tumor stage, nodal metastasis, and
distant metastasis.32 In addition to B7-H3 upregulation, we
also observed decreased surface levels of the T cell costimu-
FIGURE 3. Expression of B7 molecules by dendritic cells (DC) in lymph nodes. Single cell suspensions from tumor-infiltrated
lymph nodes from lung cancer patients (TuLN) and tumor-free lymph nodes (CoLN) were prepared and stained with the anti-
bodies indicated. The isotype control is shown in the upper left panel and the big square gate indicates the CD11c DC pop-
ulation. The upper gate depicts DC positive for the respective B7 markers. The numbers indicate the percentage of marker-
positive cells among the CD11c population. A typical example for one representative patient is shown.
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latory molecules B7-1 (CD80) and B7-2 (CD86) on DC in all
samples. Although theses differences were not statistically
significant, these results are in agreement with findings pub-
lished by Perrot et al.14 Herein, the authors report an imma-
ture DC phenotype induced by tumors, which is indicated by
reduced surface expression of B7-1 and B7-2. Moreover,
these data further support our notion that an immunosuppres-
sive phenotype of DC is induced, as immature DC are inferior
in eliciting immune responses and have rather tolerogenic
potential.
Interestingly in this series, NSCLC did not influence
the expression of either inhibitory or costimulatory B7 mol-
ecules in the respective lymph nodes. However, in these
experiments, we could only compare metastatic lymph nodes
with nonaffected lymph nodes and we cannot exclude that
even the nonmetastatic control lymph node was affected by
tumors; for example, by soluble factors produced by the
tumor, which may influence the DC phenotype because
lymph drainage in lung cancer is variable. Due to this aspect
and due to the limited number of lymph nodes examined in
our series, further investigations are clearly needed to draw
definite conclusions. Nevertheless, in the literature, no reports
about B7 expression in lymph node-acquired DC in human
cancer exist up to now.
Our data, showing that DC derived from NSCLC are
immunosuppressive, as indicated by B7-H3 upregulation, are
further supported by our results on IL-10 secretion. We have
shown that tumor-derived DC secrete elevated levels of
IL-10, which indicates a more tolerogenic and immature
phenotype. In contrast, the secretion of the immune stimula-
tory cytokine IL-12 is decreased. Thus, these data further
strengthen the notion that NSCLC is able to convert DC into
a less immunogenic cell type. Under normal conditions,
IL-10 secreting subsets of DC mediate tolerance and prevent
exacerbated immune responses such as asthma. These effects
are either mediated by IL-10 itself or by the induction of Tr1
cells, which are IL-10-producing T cells with regulatory
properties. However, our data obtained in NSCLC show that
antibodies to B7-H3 nearly completely restored the T cell
stimulatory capacity of the tumor-derived DC. Therefore, we
conclude that under tumor conditions, B7-H3 is crucial in
mediating the T cell suppressive effects of the DC. Never-
theless, we observed elevated numbers of Treg in patients
with NSCLC (data not shown), and reports by Dumitriu et
al.15 showed that NSCLC-derived DC produce high amounts
of TGF- and therefore are able to induce differentiation of
Treg in peripheral tissues. Thus, beyond the observed direct
FIGURE 4. Tumor-derived dendritic cells (DC) are inferior in
stimulating T cells. CD11c cells were enriched by magneto-
beads from organs as indicated. The upper panel shows a typi-
cal FACS plot for DC-specific markers. The lower panel shows
cocultures of CD11c cells with allogeneic CD4 T cells. After
96 hours, T cell proliferation was determined by pulsing with
3H-Thymidine. As positive control, CD4 T cells were stimu-
lated with a mixture of anti-CD3/anti-CD28 antibodies. The
figure shows CPM values of three individual experiments as
dots and the means are depicted in bars. *Significant difference
(t test; *p  0.05) between samples as indicated.
FIGURE 5. B7–H3 blockade results in enhanced stimulation of
T cells. Dendritic cell (DC)-T cell cocultures were set up as in
Figure 4 and anti-B7-H3 or respective isotype control antibod-
ies (ISO) were added. After 96 hours, T cell proliferation was
determined by pulsing the cultures with 3H-Thymidine. The
figure shows the individual data as dots and the means as bars.
*Significant difference (t test, *p  0.05) between tumor-
derived DC and B7-H3-blocked tumor-derived DC.
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immunosuppressive effects of the B7-H3, IL-10-producing
DC in NSCLC, further induction of Treg in vivo may also
contribute to immune suppression in cancer patients.
CONCLUSION
Our data indicate that (1) DC derived from NSCLC are
immunosuppressive, and (2) under tumor conditions the coin-
hibitory molecule B7-H3, among other so far unknown fac-
tors, is instrumental in mediating the T cell suppressive
effects of dendritic cells.
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FIGURE 6. Tumor-derived dendritic cells (DC) produce less
IL-12 but more IL-10. DC were purified with paramagnetic
beads and cultivated overnight in medium containing 10
ng/ml LPS. Thereafter, tissue culture supernatant was har-
vested and analyzed for presence of IL-10 and IL-12p70 as
indicated. Shown are the mean values  SD of three pa-
tients. *Significant difference (*p  0.05) between tumor
and lung.
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